[{"name": "Overall Incidence of Adverse Events", "type": "bar", "description": "Overall Incidence of Adverse Events", "units": "participants", "groups": [{"label": "Subjects with at least 1 TEAE", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 212.0}}, {"label": "Potentially-related TEAE", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 138.0}}, {"label": "Severe TEAE", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 10.0}}, {"label": "Serious TEAE", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 4.0}}, {"label": "Fatal TEAE", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 1.0}}, {"label": "Discontinued study due to TEAE", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 34.0}}]}, {"name": "Overall Incidence of Skin Reactions: Number of Events", "type": "bar", "description": "Overall Incidence of Skin Reactions: Number of Events", "units": "Events", "groups": [{"label": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 17.0}}]}, {"name": "Overall Incidence of Skin Reactions: Number of Participant Affected", "type": "bar", "description": "Overall Incidence of Skin Reactions: Number of Participant Affected", "units": "participants", "groups": [{"label": "2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 13.0}}]}, {"name": "Columbia-Suicide Severity Rating Scale (C-SSRS) Item Responses", "type": "bar", "description": "Columbia-Suicide Severity Rating Scale (C-SSRS) Item Responses", "units": "Subjects", "groups": [{"label": "Any Suicidality", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 4.0}}, {"label": "Any Suicidal Behavior", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 1.0}}, {"label": "Completed Suicide", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 0.0}}, {"label": "Actual Attempt", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 0.0}}, {"label": "Interrupted Attempt", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 0.0}}, {"label": "Aborted Attempt", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 1.0}}, {"label": "Preparatory Acts or Behavior", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 0.0}}, {"label": "Any Suicidal Ideation", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 4.0}}, {"label": "Wish to be Dead", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 0.0}}, {"label": "Non-specific Active Suicidal Thoughts", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 3.0}}, {"label": "Active Suicidal Ideation without Intent to Act", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 0.0}}, {"label": "Active Suicidal Ideation w/ Some Intent to Act", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 0.0}}, {"label": "Active Suicidal Ideation w/ Specific Plan", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 1.0}}]}, {"name": "Change From Baseline at Month 12 in Subjective Wake Time After Sleep Onset (WASO)", "type": "bar", "description": "Change From Baseline at Month 12 in Subjective Wake Time After Sleep Onset (WASO)", "units": "Minutes", "groups": [{"label": "Change From Baseline at Month 12 in Subjective Wake Time After Sleep Onset (WASO)", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": -22.7}}]}, {"name": "Change From Baseline at Month 12 in Subjective Number of Awakening After Sleep Onset (NAASO)", "type": "bar", "description": "Change From Baseline at Month 12 in Subjective Number of Awakening After Sleep Onset (NAASO)", "units": "Number of Awakenings", "groups": [{"label": "Change From Baseline at Month 12 in Subjective Number of Awakening After Sleep Onset (NAASO)", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": -0.8}}]}, {"name": "Change From Baseline in Coding Copy Subtest A or B, or Digit Symbol Substitution Test (DSST) at Month 12", "type": "bar", "description": "Change From Baseline in Coding Copy Subtest A or B, or Digit Symbol Substitution Test (DSST) at Month 12", "units": "score", "groups": [{"label": "Change From Baseline in Coding Copy Subtest A or B, or Digit Symbol Substitution Test (DSST)at Month 12", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 1.1}}]}, {"name": "Clinical Global Impression (CGI) Improvement Score as Assessed by Parent/Caregiver or Child at Month 12", "type": "bar", "description": "Clinical Global Impression (CGI) Improvement Score as Assessed by Parent/Caregiver or Child at Month 12", "units": "units on a scale", "groups": [{"label": "From Parent", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 2.6}}, {"label": "From Child", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 2.6}}]}, {"name": "Change From Baseline at Month 12 in Subjective Sleep Latency (SL)", "type": "bar", "description": "Change From Baseline at Month 12 in Subjective Sleep Latency (SL)", "units": "Minutes", "groups": [{"label": "Change From Baseline at Month 12 in Subjective Sleep Latency (SL)", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": -18.1}}]}, {"name": "Change From Baseline in Child Behavior Checklist (CBCL)", "type": "bar", "description": "Change From Baseline in Child Behavior Checklist (CBCL)", "units": "units on a scale", "groups": [{"label": "Activities scale standardized score", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 1.04}}, {"label": "Social scale standardized score", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 0.94}}, {"label": "School scale standardized score", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 0.02}}, {"label": "Total competence standardized score", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 1.02}}, {"label": "Internalizing problems standardized score", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 0.19}}, {"label": "Externalizing problems standardized score", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 0.29}}, {"label": "Total problems standardized score", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 0.19}}]}, {"name": "Change From Baseline at Month 12 in Subjective Total Sleep Time (TST).", "type": "bar", "description": "Change From Baseline at Month 12 in Subjective Total Sleep Time (TST).", "units": "Minutes", "groups": [{"label": "Change From Baseline at Month 12 in Subjective Total Sleep Time (TST).", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 45.3}}]}, {"name": "Change From Baseline in Pediatric Daytime Sleepiness Scale (PDSS)at Month 12", "type": "bar", "description": "Change From Baseline in Pediatric Daytime Sleepiness Scale (PDSS)at Month 12", "units": "units on a scale", "groups": [{"label": "Change From Baseline in Pediatric Daytime Sleepiness Scale (PDSS)at Month 12", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": -3.9}}]}, {"name": "Change From Baseline in Conners' Continuous Performance Test II (CCPT II)", "type": "bar", "description": "Change From Baseline in Conners' Continuous Performance Test II (CCPT II)", "units": "percentage of score", "groups": [{"label": "Omissions % Percentile", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 10.285}}, {"label": "Commissions % Percentile", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": -5.98}}, {"label": "Hit RT Percentile", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 5.933}}, {"label": "Hit RT Std Error Percentile", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 8.747}}, {"label": "Variability Percentile", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 8.781}}, {"label": "Detectability (d') Percentile", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": -3.614}}, {"label": "Responsive Style (beta) Percentile", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": -3.614}}, {"label": "Perseverations % Percentile", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 4.807}}, {"label": "Hit RT Block Change Percentile", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 0.213}}, {"label": "Hit SE Block Change Percentile", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": -2.919}}, {"label": "Hit RT ISI Change Percentile", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 8.07}}, {"label": "Hit SE ISI Change Percentile", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 8.27}}, {"label": "Confidence Index", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 8.471}}]}, {"name": "Change From Baseline in Pediatric Quality of Life Scale", "type": "bar", "description": "Change From Baseline in Pediatric Quality of Life Scale", "units": "units on a scale", "groups": [{"label": "Physical Summary Score", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": -1.31}}, {"label": "Psychosocial Summary Score", "data": {"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)": 2.14}}]}]